Print
Email
Print Edition StoriesWednesday, August 13, 2008
Stromedix kidney transplant therapy gets FDA orphan drug status
By Mass High Tech Staff
The U.S. Food and Drug Administration has granted orphan drug status to Cambridge biotech Stromedix Inc.’s STX-100, a treatment for chronic allograft nephropathy, a cause of transplant failure in patients with kidney transplants.
The condition currently has no treatment approved by the FDA, though it affects about 20 percent of patients waiting for a kidney retransplant, according to Stromedix officials.
Stromedix licensed STX-100, a humanized monoclonal antibody, from Biogen Idec Inc. last year and began Phase 1 clinical trials on it this year. The company announced in April that it had raised $25 million in a Series B round of venture capital to fund development of STX-100. New Leaf Venture Partners, of New York City and Menlo Park, Calif., led the round, which included investments from Boston area firms Bessemer Venture Partners and Atlas Venture. Other investors were Frazier Healthcare Ventures of Seattle and Red Abbey Venture Partners of Baltimore, Stromedix officials said.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
